Medical condition
Arthritis
Arthritis is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- leflunomide (APO-LEFLUNOMIDE) Antineoplastic and immunomodulating agents (L04)
- azathioprine (APO-AZATHIOPRINE) Antineoplastic and immunomodulating agents (L04)
- apremilast (OTEZLA) Antineoplastic and immunomodulating agents (L04)
- febuxostat (ADENURIC) Musculo-skeletal system (M04)
- upadacitinib (RINVOQ) Antineoplastic and immunomodulating agents (L04)
- tofacitinib (XELJANZ) Antineoplastic and immunomodulating agents (L04)
- guselkumab (TREMFYA) Antineoplastic and immunomodulating agents (L04)
- golimumab (SIMPONI) Antineoplastic and immunomodulating agents (L04)
- anakinra (KINERET) Antineoplastic and immunomodulating agents (L04)
- etanercept (BRENZYS) Antineoplastic and immunomodulating agents (L04)
- deucravacitinib (SOTYKTU) Antineoplastic and immunomodulating agents (L04)
- certolizumab pegol (CIMZIA) Antineoplastic and immunomodulating agents (L04)
Latest Arthritis news
UCB's Bimzelx Triumphs Over AbbVie's Skyrizi in Psoriatic Arthritis
UCB's Bimzelx has shown superior efficacy compared to AbbVie's Skyrizi in treating psoriatic arthritis, marking a significant milestone in the competitive landscape. This article analyzes the implications for pharmaceutical business development teams.
Immunovant Shares Surge on Arthritis Trial Data: What It Means for Pharma
Immunovant's recent trial data has led to a significant surge in its shares. This article explores the implications for pharmaceutical teams and investors.
Contineum Therapeutics PIPE-791 Shows Positive Phase 1b Results for Chronic Osteoarthritis Pain
Contineum Therapeutics reports positive Phase 1b trial data for PIPE-791, a non-opioid LPA1 receptor antagonist for chronic osteoarthritis pain treatment.